- Current report filing (8-K)
April 14 2010 - 2:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 8, 2010
MusclePharm Corporation
(Exact Name of Registrant as Specified in its Charter)
Nevada 000-53166 77-0664193
(State or Other Jurisdiction (Commission File No.) (I.R.S. Employer
of Incorporation) Identification
Number)
3390 Peoria St., #307, Aurora, CO 80010
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (800) 210-7369
|
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors and Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
(b) and (c). The Company's Board of Directors has determined to change
the titles of its two highest officers. Brad J. Pyatt, who formerly served
as the President will now serve as Chief Executive Officer of the Company and
Cory Gregory, who formerly served as Executive Vice President will now serve
as the President of the Company. There were no changes in the compensation
of these two officers as a result of these changes.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
MusclePharm Corporation
By: /s/ Brad J. Pyatt
Name: Brad J. Pyatt
Title: President
Dated: April 14, 2010
|
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From May 2024 to Jun 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2023 to Jun 2024